2025
Blomain E, Soudi S, Wang Z, Somani A, Subramanian A, Nouth S, Oladipo E, New C, Kenney D, Nemat-Gorgani N, Kindler T, Avedian R, Steffner R, Mohler G, Hiniker S, Chin A, Kalbasi A, Binkley M, Fried M, Gaida M, van de Rijn M, Moding E
Evolutionary Pressures Shape Undifferentiated Pleomorphic Sarcoma Development and Radiotherapy Response
Cancer Res. 2025
Radiotherapy is an integral component in the treatment of many types of cancer, with approximately half of cancer patients receiving radiotherapy. Systemic therapy applies pressure that can select for resistant tumor subpopulations, underscoring the importance of understanding how radiation impacts tumor evolution to improve treatment outcomes. We integrated temporal genomic profiling of 120 spatially distinct tumor regions from 20 patients with undifferentiated pleomorphic sarcomas (UPS), longitudinal circulating tumor DNA (ctDNA) analysis, and evolutionary biology computational pipelines to study UPS evolution during tumorigenesis and in response to radiotherapy. Most unirradiated UPS displayed initial linear evolution followed by subsequent branching evolution with distinct mutational processes during early and late development. Metrics of genetic divergence between regions provided evidence of strong selection pressures during UPS development that further increased during radiotherapy. Subclone abundance changed following radiotherapy with subclone contraction tied to alterations in calcium signaling, and inhibiting calcium transporters radiosensitized sarcoma cells. Finally, ctDNA analysis accurately measured subclone abundance and enabled non-invasive monitoring of subclonal changes. These results demonstrate that radiation exerts selective pressures on UPS and suggest that targeting radioresistant subclonal populations could improve outcomes after radiotherapy.
Schorn S, Fritz A, Kaissis G, Gaida MM, Steiger K, Jäger C, Schlitter AM, Braren R, Friess H, Demir IE, Ceyhan GO.
Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma
Surgery. 2025
Background: In pancreatic ductal adenocarcinoma, neural invasion is being increasingly recognized as an unfavorable predictor of patient outcomes. Neural invasion severity seems to have a stronger clinical impact on patient prognosis than neural invasion status alone. Therefore, this study aims to assess the impact of severity of neural invasion on overall survival and disease-free survival in pancreatic ductal adenocarcinoma.
Materials: To assess the impact of intrapancreatic neural invasion severity, tumor specimens resected from patients with pancreatic ductal adenocarcinoma between 2007 and 2014 were systematically re-evaluated, and neural invasion severity was determined using the standardized neural invasion severity score.
Results: In our cohort (n = 216), an increased neural invasion severity score was associated with markedly shorter overall survival in pancreatic head ductal adenocarcinoma (neural invasion severity score low: 22.8 months vs neural invasion severity score high: 17.6 months: P = .001). An external European validation cohort confirmed these results and showed significantly better survival of patients with lower neural invasion (20.5 vs 15.4 months, P = .026). The disease-free survival time was also substantially decreased in patients with pancreatic head pancreatic ductal adenocarcinoma and increased neural invasion severity (neural invasion severity score low: 19.1 months vs neural invasion severity score high: 10.4 months; P = .004). Moreover, the neural invasion severity score was an important independent factor influencing overall survival (hazards ratio 1.024, P = .04) and disease-free survival (hazards ratio 1.03, P = .01) using an adjusted Cox proportional hazards model. Importantly, higher neural invasion severity score leads to significantly more and earlier local recurrence than to distant tumor recurrence.
Conclusion: Neural invasion severity is a powerful independent factor influencing overall survival and local recurrence in patients with pancreatic ductal adenocarcinoma. Therefore, individuals with high neural invasion severity score values should be regarded as a specific subgroup of pancreatic ductal adenocarcinoma patients and may benefit from more tailored postoperative oncologic therapy.
Lopez J, Powles T, Braiteh F, Löwer M, et al.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Med. 2025
Benderski K, Schneider P, Kordeves P, Fichter M, Schunke J, De Lorenzi F, Durak F, Schrörs B, Akilli Ö, Kiessling F, Bros M, Diken M, Grabbe S, Schattenberg JM, Lammers T, Sofias AM, Kaps L.
A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing
Pharmacol Res . 2024
Gleue L, Graefen B, Voigt M, Schupp J, Schneider D, Fichter M, Kuske M, Mailaender V, Tuettenberg A, Helm M.
Dual Centrifugation-Based Screening for pH-Responsive Liposomes
ChemMedChem. 2024
Lüttman F F, Kim K-P, Kim J.
Spliceosomal repression: unleashing human cell totipotency
Signal Transduction and Targeted Therapy, 2024
Schramm E, Becker V, Palagi I, Müller M, Rösler T, Durak F, Ebering A, Karram K, von Stebut E, Schmeisser MJ, Waisman A.
Constitutive expression of the deubiquitinating enzyme CYLD does not affect microglia phenotype or function in homeostasis and neuroinflammation
J Mol Med (Berl). 2024
Bresadola L, Weber D, Ritzel C, Löwer M, Bukur V, Akilli-Öztürk Ö, Schuster C, Gargano A, Becker J, Mehanna H, Schrörs B, Vascotto F, Sahin U & Kong, A.
Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma
BJC Reports volume 2, Article number: 62 (2024)
Muik A, Quandt J, Lui BG, Bacher M, Lutz S, Grünenthal M, Toker A, Grosser J, Ozhelvaci O, Blokhina O, Shpyro S, Vogler I, Salisch N, Türeci Ö, Sahin U.
Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
Cell Rep. 2024
Mohamed S, Barlemann A, Steinle V, Nonnenmacher T, Güttlein M, Hackert T, Loos M, Gaida M, Kauczor H, Klauss M & Mayer P.
Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery.
Sci Rep 14, 19783 (2024)
Muhammad S. Alam M, Gaida M, Witzel H, Otsuka S, Abbasi A, Guerin T, Abdelmaksoud A, Wong N, Cam M, Kozlov, S, Ashwell J.
TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function
Cell Reports Medicine, August 22 (2024)
Ahrberg Y, Dallmann J, Freitag J, Hassan A, Jung C, Kiefer J, Muralidharan AM, Peter M, Beck JD..
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy
Hum Vaccin Immunother. 2024
Schneider P, Zhang H, Simic L, Dai Z, Schrörs B, Akilli-Öztürk Ö, Lin J, Durak F, Schunke J, Bolduan V, Bogaert B, Schwiertz D, Schäfer G, Bros M, Grabbe S, Schattenberg JM, Raemdonck K, Koynov K, Diken M, Kaps L, Barz M
Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer-Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma
Advanced Materials 2024
Yıldız A, Hasani A, Hempel T, Köhl N, Beicht A, Becker R, Hubich-Rau S, Suchan M, Poleganov M, Sahin U, Beissert T
Trans-amplifying RNA expressing functional miRNA mediates target gene suppression and simultaneous transgene expression
Molecular Therapy: Nucleic Acids 2024
Khristenko E, Gaida MM, Tjaden C, Steinle V, Loos M, Krieger K, Weber TF, Kauczor HU, Klauß M, Mayer P
Imaging differentiation of solid pseudopapillary neoplasms and neuroendocrine neoplasms of the pancreas
European Journal of Radiology Open 2024
Lang F, Sorn P, Suchan M, Heinrich A, Albrecht C, Köhl N, Beicht A, Riesgo-Ferreiro P, Holsträter C, Schrörs B, Weber D, Löwer M, Sahin U, Ibn-Salem J
Prediction of tumor-specific splicing from somatic mutations as a source of neoantigen candidates
Bioinformatics Advances, 2024
Mayer P, Hausen A, Steinle V, Bergmann F, Kauczor, H, Loos M, Roth W, Klauss M, Gaida M.
The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding
Langenbecks Arch Surg . 2024
De Sanctis F, Dusi S, Caligola S, Anselmi C, Petrova V, Rossi B, Angelini G, Erdeljan M, Wöll S, Schlitter A M, Metzler T, Steiger K, Borok Z, Bailey P, Bauer A, Halin C, Boschi F, Giugno R, Canè S, Lawlor R, Corbo V, Scarpa A, Constantin G, Ugel S, Vascotto F, Sahin U, Türeci Ö, Bronte V
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer
Immunity, 2024
Köhler A, Geiselhöringer AL, Kolland D, Kreft L, Wichmann N, Hils M, Pasztoi M, Zurkowski E, Vogt J, Kübelbeck T, Biedermann T, Schmitz I, Hansen W, Kramer D, Gaida MM, Schmidt-Weber CB, Hoevelmeyer N, Ohnmacht C
The atypical IκB family member Bcl3 determines differentiation and fate of intestinal RORγt+ regulatory T cell subsets
Mucosal Immunol. 2024
Neuhaus F, Lieber S, Shinkevich V, Steitz AM, Raifer H, Roth K, Finkernagel F, Worzfeld T, Burchert A, Keber C, Nist A, Stiewe T, Reinartz S, Beutgen VM, Graumann J, Pauck K, Garn H, Gaida M, Müller R, Huber M.
Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells
Clin Transl Med 2024
López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida M M, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin M-L, Alexandra Aicher A, García de Paredes A G, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Alfredo Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo V J, Heeschen C, Bruno Sainz Jr B
The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells
Gut 2024
Yıldız A, Răileanu C, Beissert T
Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines
Viruses 2024
Vega-Sendino M, Lüttmann F, T Olbrich T, Yanpu Chen Y, Kuenne C, Stein P, Tillo D, Carey G, Zhong J, Savy V, Radonova L, Lu T, Saykali B, Kim K, Domingo C, Schüler L, Günther S, Bentsen M, Bosnakovski D, Schöler H, Kyba M, Maity T, Jenkins L, Looso M, Williams C, Kim J, Ruiz S
The homeobox transcription factor DUXBL controls exit from totipotency
Nat Genet. 2024
Beck J, Diken M, Suchan M, Streuber M, Diken E, Kolb L, Allnoch L, Vascotto F, Peters D, Beißert T, Akilli-Öztürk Ö, Türeci Ö, Kreiter- S, Vormehr M, Sahin U
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers
Cancer Cell 2024
Kespohl M, Goetzke CC, Althof N, Bredow C, Kelm N, Pinkert S, Bukur T, Bukur V, Grunz K, Kaur D, Heuser A, Mülleder M, Sauter M, Klingel K, Weiler H, Berndt N, Gaida MM, Ruf W, Beling A
TF-FVIIa PAR2-β-Arrestin in Mouse Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection
Arterioscler Thromb Vasc Biol. 2024
Park J, Kim Ju, Shin B, Schöler H R, Kim Jo, Kim K-P
Inducing Pluripotency in Somatic Cells: Historical Perspective and Recent Advances
Int J Stem Cells 2024
Göbel S, Braun AS, Hahad O, von Henning U, Brandt M, Keller K, Gaida MM, Gori T, Schultheiss HP, Escher F, Münzel T, Wenzel P.
Etiologies and predictors of mortality in an all-comer population of patients with non-ischemic heart failure
Clin Res Cardiol. 2024
Salomon N, Helm A, Selmi A, Fournier C, Diken M, Schrörs B, Scholz M, Kreiter S, Durante M, Vascotto F
Carbon ion and photon radiotherapy show enhanced anti-tumoral therapeutic efficacy with neoantigen RNA-LPX vaccines in preclinical colon carcinoma models
International Journal of Radiation Oncology, Biology, Physics (2023)
Schleussner N, Cauchy P, Franke V, Giefing M, Fornes O, Vankadari N, Assi SA, Costanza M, Weniger MA, Akalin A, Anagnostopoulos I, Bukur T, Casarotto MG, Damm F, Daumke O, Edginton-White B, Gebhardt JCM, Grau M, Grunwald S, Hansmann ML, Hartmann S, Huber L, Kärgel E, Lusatis S, Noerenberg D, Obier N, Pannicke U, Fischer A, Reisser A, Rosenwald A, Schwarz K, Sundararaj S, Weilemann A, Winkler W, Xu W, Lenz G, Rajewsky K, Wasserman WW, Cockerill PN, Scheidereit C, Siebert R, Küppers R, Grosschedl R, Janz M, Bonifer C, Mathas S.
Transcriptional reprogramming by mutated IRF4 in lymphoma
Nat Commun. 2023 Nov 7;14(1):6947
Bähr-Mahmud H, Ellinghaus U, Stadler CR, Fischer L, Lindemann C, Chaturvedi A, Diekmann J, Wöll S, Biermann I, Hebich B, Scharf C, Siefke M, Roth AS, Rao M, Brettschneider K, Ewen EM, Şahin U, Türeci Ö.
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
Oncoimmunology . 2023 Oct 16;12(1):2255041
Kohlruss M, Chakraborty S, Hapfelmeier A, Jesinghaus M, Slotta-Huspenina J, Novotny A, Sisic L, Gaida MM, Ott K, Weichert W, Pfarr N, Keller G.
Low microsatellite instability: A distinct instability type in gastric cancer?
J Cancer Res Clin Oncol . 2023 Oct 11. doi: 10.1007/s00432-023-05430-6
Lang F, Sorn P, Schrörs B, Weber D, Kramer S, Sahin U, Löwer L
Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
iScience, Volume 26, Issue 11, 17 November 2023, 108014
Dallmann J, Freitag J, Jung C, Khinvasara K, Merz L, Peters D, Schork M, Beck JD
CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy
Immunooncol Technol . 2023 Sep 12:20:100397
Bosnakovski D, Toso EA, Ener ET, Gearhart MD, Yin L, Lüttmann FF, Magli A, Shi K, Kim J, Aihara H, Kyba M
Antagonism among DUX family members evolved from an ancestral toxic single homeodomain protein
iScience. 2023 Sep 2;26(10):107823
Hefermehl AK, Hensen SM, Versantvoort C, Rothermel A, Sahin U
Automated glycan-bead coupling for high throughput, highly reproducible anti-glycan antibody analysis
SLAS Technology 2023
Wilhelmy C, Keil IS, Uebbing L, Schroer MA, Franke D, Nawroth T, Barz M, Sahin U, Haas H, Diken M, Langguth P
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Pharmaceutics 2023, 15(8), 2068
Kriegsmann M, Kriegsmann K, Steinbuss G, Zgorzelski C, Albrecht T, Heinrich S, Farkas S, Roth W, Dang H, Hausen A, Gaida M.
Implementation of deep learning in liver pathology optimizes diagnosis of benign lesions and adenocarcinoma metastasis
Clin Transl Med. 2023; 13:e1299
Peri A, Salomon N , Wolf, Y, Kreiter S, Diken M, Samuels Y
The landscape of T cell antigens for cancer immunotherapy
Nat Cancer . 2023 Jul 6.
Bukur T, Riesgo-Ferreiro, Sorn P, Gudimella R, Hausmann J, Roesler T, Loewer M, Schroers B, and Sahin U
CoVigator—A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants
Viruses 2023, 15(6), 1391
Yousuf S, Qiu M, Voithenberg LVv, Hulkkonen J, Macinkovic I, Schulz AR, Hartmann D, Mueller F, Mijatovic M, Ibberson D, AlHalabi KT, Hetzer J, Anders S, Bruene B, Mei HE, Imbusch CD, Brors B, Heikenwaelder M, Gaida MM, Buechler MW, Weigert A, Hackert T, Roth S
Spatially resolved multi-omics single-cell analyses inform mechanisms of immune-dysfunction in pancreatic cancer
Gastroenterology 2023
As pancreatic ductal adenocarcinoma (PDAC) continues to be recalcitrant to therapeutic interventions including poor response to immunotherapy, albeit effective in other solid malignancies, a more nuanced understanding of the immune microenvironment in PDAC is urgently needed. We aimed to unveil a detailed view of the immune micromilieu in PDAC using a spatially-resolved multimodal single cell approach. METHODS We applied single cell RNA sequencing, spatial transcriptomics, multiplex immunohistochemistry and mass cytometry to profile the immune compartment in treatment naive PDAC tumors and matched adjacent normal pancreatic tissue, as well as in the systemic circulation. We determined prognostic associations of immune signatures, and performed a meta-analysis of the immune microenvironment in PDAC and lung adenocarcinoma (LUAD) on single-cell level. RESULTS We provide a spatially-resolved fine map of the immune landscape in PDAC. We substantiate the exhausted phenotype of CD8 T cells and immunosuppressive features of myeloid cells, and highlight immune subsets with potentially underappreciated roles in PDAC, that diverge from immune populations within adjacent normal areas, particularly CD4 T cell subsets and NKT cells that are terminally exhausted and acquire a regulatory phenotype. Differential analysis of immune phenotypes in PDAC and LUAD revealed the presence of extraordinarily immunosuppressive subtypes in PDAC, along with a distinctive immune checkpoint composition. CONCLUSION Our study sheds light on the multilayered immune dysfunction in PDAC and presents a holistic view of the immune landscape in PDAC and LUAD, providing a comprehensive resource for functional studies and the exploration of therapeutically actionable targets in PDAC.
Hiltner T, Kohlruss M, Herz A-L, Lorenzen S, Novotny A, Hapfelmeier A, Jesinghaus M, Slotta Huspenina J, Sisic L, Gaida MM, Weichert W, Ott K, Keller G
Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients
J Cancer Res Clin Oncol 2023
Saerchen V, Reindl L, Wiedemann S, Shanmugalingam S, Bukur T, Becker J, Suchan M, Ullrich E, Vogler M.
Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids
Cells 2023, 12(6), 906
Schroers B, Hos B, Yildiz I, Loewer M, Lang F, Holtstraeter C, Becker J, Vormehr M, Sahin U, Ossendorp F, Diken M
MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
Front. Immunol., 08 March 2023
Jeong YJ, Knutsdottir H, Shojaeian F, Lerner M, Wissler M, Henriet E, Ng T, Datta S, Navarro-Serer B, Chianchiano P, Kinny-Köster B, Zimmerman J, Stein-O'Brien G, Gaida M, Eshleman J, Lin M, Fertig E, Ewald A, Bader J, Wood LD
Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion
J Clin Invest . 2023 Mar 7
Picard FSR, Lutz V, Brichkina A, Neuhaus F, Ruckenbrod T, Hupfer A, Raifer H, Klein M, Bopp T, Pfefferle PI, Savai R, Prinz I, Waisman A, Moos S, Chang HD, Heinrich S, Bartsch DK, Buchholz M, Singh S, Tu M, Klein L, Bauer C, Liefke R, Burchert A, Chung HR, Mayer P, Gress TM, Lauth M, Gaida M, Huber M.
IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
Gut. 2023 Feb 9:gutjnl-2022-327855.
Perkovic M, Gawletta S, Hempel T, Brill S, Nett E, Sahin U, Beissert T.
A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice
Mol Ther. 2023 Jan 23:S1525-0016(23)00019-9
Stern L, Boehme LF, Goetz MR, Nitschke C, Giannou A, Zhang T, Gungor C, Reeh M, Izbicki JR, Fliegert R, Hausen A, Giese N, Hackert T, Niv MY, Heinrich S, Gaida MM, and Ghadban T.
Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin.
Int J Oncol 62(1):6
Yan B, Liu L, Zhao L, Hinz U, Luo Y, An X, Gladkich J, de la Torre C, Huang Z, Schrapel D, Gross W, Fortunato F, Schäfer M, Gaida MM, Herr I.
Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma.
Matrix Biol. 2022 Nov 11:S0945-053X(22)00134-2.
Krähling V, Erbar S, Kupke A, Nogueira SS, Walzer KC, Berger H, Dietzel E, Halwe S, Rohde C, Sauerhering L, Aragão-Santiago L, Moreno Herrero J, Witzel S, Haas H, Becker S, Sahin U.
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection.
Mol Ther. 2022 Oct 27:S1525-0016(22)00623-2.
Wang J, Weiss T, Neidert MC, Toussaint NC, Naghavian R, Moreno Sellés C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin JH, McKay R, Wu CJ, Lutterotti A, Sospedra M, Moch H, Greiner EF, Bodenmiller B, Regli L, Weller M, Roth P, Martin R.
Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma.
Clin Cancer Res. 2022 Oct 13:CCR-22-1741.
Schmidt C, Hastert FD, Gerbeth J, Beissert T, Sahin U, Perkovic M, Schnierle BS.
A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces Potent Chikungunya and Ross River Virus Specific Immune Responses.
Vaccines (Basel). 2022 Aug 23;10(9):1374.
Birtel M, Voss RH, Reinhard K, Rengstl B, Ouchan Y, Michel K, Hayduk N, Tillmann B, Becker R, Suchan M, Theobald M, Oehm P, Türeci Ö, Sahin U
A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination
Cancer Res. Comm. 2022. 2 (8): 827–841
Sahu SK, Agirre E, Inayatullah M, Mahesh A, Tiwari N, Lavin DP, Singh A, Strand S, Diken M, Luco RF, Belmonte JCI, Tiwari VK
A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development
Nat. Cell Biol. 2022 Aug; 24(8):1265-1277
Fonteneau G, Redding A, Hoag-Lee H, Sim ES, Heinrich S, Gaida MM, and Grabocka E
Stress Granules determine the Development of Obesity-associated Pancreatic Cancer.
Cancer Discov. 2022 Aug 5;12(8):1984-200
Brindl N, Boekhoff H, Bauer AS, Gaida MM, Dang HT, Kaiser J, Hoheisel JD, Felix K
Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy
Cancers 2022, 14, 3562
Muik A, Adams 3rd HC, Gieseke F, Altintas I, Schoedel KB, Blum JM, Sänger B, Burm SM, Stanganello E, Verzijl D, Spires VM, Vascotto F, Toker A, Quinkhardt J, Fereshteh M, Diken M, Satijn DPE, Kreiter S, Ahmadi T, Breij ECW, Türeci Ö, Sasser K, Sahin U, Jure-Kunkel M.
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Journal for Immunotherapy of Cancer. 2022 Jun;10(6):e004322.
Schmidt C, Haefner E, Gerbeth J, Beissert T, Sahin U, Perkovic M, Schnierle BS.
A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections.
Nucleic Acids. 2022 Jun;28:743-754.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I.
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Cancer Discov. 2022 May 2;12(5):1248-1265.
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U.
Identification of neoantigens for individualized therapeutic cancer vaccines.
Nat Rev Drug Discov. 2022 Apr;21(4):261-282.
Voss M, Pinkert S, Kespohl M, Gimber N, Klingel K, Schmoranzer J, Laue M, Gaida M, Kloetzel PM, and Beling A
A Conserved Cysteine Residue in Coxsackievirus B3 Protein 3A with Implication for Elevated Virulence.
Viruses. 2022 Apr 7;14(4):769
Weber D, Ibn-Salem J, Sorn P, Suchan M, Holtsträter C, Lahrmann U, Vogler I, Schmoldt K, Lang F, Schrörs B, Löwer M, Sahin U.
Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens.
Nat Biotechnol. 2022 Apr 4.
Kaps L, Huppertsberg A, Choteschovsky N, Klefenz A, Durak F, Schrörs B, Diken M, Eichler E, Rosigkeit S, Schmitt S, Leps C, Schulze A, Foerster F, Bockamp E, De Geest B, Koynov K, Räder H, Stefan Tenzer S, Marini F, Schuppan D, Nuhn, L.
pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.
Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2122310119.
Schäfer MEA, Keller F, Schumacher J, Haas H, Vascotto F, Sahin U, Hafner M, Rudolf R.
3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors.
Cells. 2022 Mar 17;11(6):1026.
Muik A, Altintas I, Gieseke F, Schoedel KB, Burm SM, Toker A, Salcedo TW, Verzijl D, Eisel D, Grunwitz C, Kranz LM, Vormehr M, Satijn DPE, Diken M, Kreiter S, Sasser K, Ahmadi T, Türeci Ö, Breij ECW, Jure-Kunkel M, Sahin U.
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Oncoimmunology. 2022 Feb 16;11(1):2030135.
Riesgo-Ferreiro P, Gudimella R, Bukur T, Patrick Sorn P, Rösler T, Schrörs B, Löwer M.
In silico analysis of predicted differential MHC binding and CD8+ T-cell immune escape of SARS-CoV-2 B.1.1.529 variant mutant epitopes.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv.
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, von Deimling A, Wick W, Sahm F, Platten M, Bunse L.
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Clin Cancer Res. 2022 Jan 15;28(2):378-389.
Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, Türeci Ö, Sahin U, Vascotto F. (2021)
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer.
Cancer Immunol Immunother. 2021 Dec 31.
Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, Voss RH, Diken M, Asad S. (2021)
CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
J Transl Med. 2021 Nov 27;19(1):482.
Weiden J, Schluck M, Ioannidis M, van Dinther EAW, Rezaeeyazdi M, Omar F, Steuten J, Voerman D, Tel J, Diken M, Bencherif SA, Figdor CG, Verdoes M. (2021)
Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots.
ACS Biomater. Sci. Eng. https://pubs.acs.org/doi/10.1021/acsbiomaterials.0c01648.
Tadmor AD, Phillips R. (2021)
MCRL: using a reference library to compress a metagenome into a nonredundant list of sequences, considering viruses as a case study.
Bioinformatics, btab703.
Schrörs B, Riesgo-Ferreiro P, Sorn P, Gudimella R, Bukur T, Rösler T, Löwer M, Sahin U. (2021)
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates.
PLoS One. 16(9):e0249254.
Formes H, Bernardes JP, Mann A, Bayer F, Pontarollo G, Kiouptsi K, Schäfer K, Attig S, Nikolova T, Hofmann TG, Schattenberg JM, Todorov H, Gerber S, Rosenstiel P, Bopp T, Sommer F, Reinhardt C. (2021)
The gut microbiota instructs the hepatic endothelial cell transcriptome.
iScience. 24(10):103092.
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karikó K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D. (2021)
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Sci Transl Med. 13(610):eabc7804.
Kappel C, Seidl C, Medina-Montano C, Schinnerer M, Alberg I, Leps C, Sohl J, Hartmann AK, Fichter M, Kuske M, Schunke J, Kuhn G, Tubbe I, Paßlick D, Hobernik D, Bent R, Haas K, Montermann E, Walzer K, Diken M, Schmidt M, Zentel R, Nuhn L, Schild H, Tenzer S, Mailänder V, Barz M, Bros M, Grabbe S. (2021)
Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial Cells.
ACS Nano 15(9):15191-15209.
Bresadola L, Weber D, Ritzel C, Löwer M, Bukur V, Akilli-Öztürk Ö, Becker J, Mehanna H, Schrörs B, Vascotto F, Sahin U, Kong A. (2021)
Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient.
Int J Mol Sci. 2021 Jul 15;22(14):7583.
Lang F, Ferreiro PR, Löwer M, Sahin U, Schrörs B. (2021)
NeoFox: annotating neoantigen candidates with neoantigen features
Bioinformatics. 2021 May 10:btab344.
Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. (2021)
mRNA therapeutics in cancer immunotherapy.
Mol Cancer. 20(1):69. doi: 10.1186/s12943-021-01348-0.
Dölen Y, Gileadi U, Chen JL, Valente M, Creemers JHA, Van Dinther EAW, van Riessen NK, Jäger E, Hruby M, Cerundolo V, Diken M, Figdor CG, de Vries IJM. (2021)
PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.
Front Immunol. 12:641703.
Miederer M, Pektor S, Miederer I , Bausbacher N, Keil IS, Hefesha H, Haas H, Sahin U, Diken M. (2021)
Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA.
EJNMMI Res 11, 14.
Aravamudhan S, Türk C, Bock T, Keufgens L, Nolte H, Lang F, Krishnan RK, König T, Hammerschmidt P, Schindler N, Brodesser S, Rozsivalova DH, Rugarli E, Trifunovic A, Brüning J, Langer T, Braun T, Krüger M. (2021)
Phosphoproteomics of the developing heart identifies PERM1 – An outer mitochondrial membrane protein.
J Mol Cell Cardiol. 154:41-59.
Vogel AB, Kanevsky I, Che Y, et al. (2021)
Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Nature. https://doi.org/10.1038/s41586-021-03275-y.
Costa B, Fletcher MNC, Boskovic P, Ivanova EL, Eisemann T, Lohr S, Bunse L, Löwer M, Burchard S, Korshunov A, Coltella N, Cusimano M, Naldini L, Liu HK, Platten M, Radlwimmer B, Angel P, Peterziel H. (2021)
A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors.
Cancers (Basel).13(2):230.
Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J, Diken M, Kreiter S, Yogev N, Waisman A, Karikó K, Türeci Ö, Sahin U. (2021)
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.
Science. 371(6525):145-153.
Sethi R, Becker J, de Graaf J, Löwer M, Suchan M, Sahin U, Weber D
Integrative analysis of structural variations using short-reads and linked-reads yields highly specific and sensitive predictions
PLoS Comput Biol 16(11): e1008397
Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, Türeci Ö. (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Nature.
Schrörs B, Boegel S, Albrecht C, Bukur T, Bukur V, Holtsträter C, Ritzel C, Manninen K, Tadmor AD, Vormehr M, Sahin U, Löwer M. (2020)
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model.
Frontiers in Oncology.
Nadja Salomon (2020)
A liposomal RNA vaccine augments the antitumor activity of local radiotherapy in mice
Taylor & Francis Online
Salomon N, Vascotto F, Selmi A, Vormehr M, Quinkhardt J, Bukur T, Schrörs B, Löwer M, Diken M, Türeci Ö, Sahin U, Kreiter S. (2020)
A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice.
Oncoimmunology. 9:1771925.
Barea Roldán D, Grimmler M, Hartmann C, Hubich-Rau S, Beiβert T, Paret C, Cagna G, Rohde C, Wöll S, Koslowski M, Türeci O, Sahin U. (2020)
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.
Oncotarget. 11:1862-1875.
Schöpf B, Weissensteiner H, Schäfer G, Fazzini F, Charoentong P, Naschberger A, Rupp B, Fendt L, Bukur V, Giese I, Sorn P, Sant’Anna-Silva AC, Iglesias-Gonzalez J, Sahin U, Kronenberg F, Gnaiger E, Klocker H. (2020)
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation.
Nat. Comm. 11(1):1487.
Holtsträter C, Schrörs B, Bukur T, Löwer M. (2020)
Bioinformatics for Cancer Immunotherapy.
In: Methods Mol Biol. 2120:1-9. Springer.
Vormehr M, Diken M, Türeci Ö, Sahin U, Kreiter S. (2019)
Personalized Neo-Epitope Vaccines for Cancer Treatment.
In: Theobald M. (eds) Current Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research. 214:153-167. Springer.
Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, Christ E, Weber D, Suchan M, Bukur T, Birtel M, Jahndel V, Mroz K, Hobohm K, Kranz L, Diken M, Kühlcke K, Türeci Ö, Sahin U. (2020)
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.
Science. 367:446-453.
Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, Türeci Ö, Sahin U. (2019)
A trans-amplifying RNA vaccine strategy for induction of potent protective immunity.
Mol Ther. pii: S1525-0016(19)30412-5.
Sorn P, Holtsträter C, Löwer M, Sahin U, Weber D. (2019)
ArtiFuse – Computational validation of fusion gene detection tools without relying on simulated reads.
Bioinformatics. pii: btz613.
Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, Kreiter S, Türeci Ö, Sahin U. (2019)
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory.
Oncoimmunology. 8:e1629259.
Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, Sahin U. (2019)
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.
Oncoimmunology. 8:e1601480.
Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, Bukur V, Kuhn AN, Türeci Ö, Sahin U. (2019)
Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening.
Mol Ther. 27:824-836.
Vormehr M, Türeci Ö, Sahin U. (2019)
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines.
Annu Rev Med. 70:395-407.
Vormehr M, Reinhard K, Blatnik R, Josef K, Beck JD, Salomon N, Suchan M, Selmi A, Vascotto F, Zerweck J, Wenschuh H, Diken M, Kreiter S, Türeci Ö, Riemer AB, Sahin U. (2018)
A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo.
Oncoimmunology.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. (2018)
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature
Fiore A, Ugel S, Sanctis FD, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V. (2018)
Induction of immunosuppressive functions and NF-kB by FLIP in monocytes.
Nat Commun. 9:5193
Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F, Lammers T, Shi Y. (2018)
Nanomedicine and macroscale materials in immuno-oncology.
Chem Soc Rev. 48(1):351-381
Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E and Melero I. (2018)
An RNA toolbox for cancer immunotherapy.
Nat Rev. Drug Discov. 17(10):751-767
Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M. (2018)
In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET.
EJNMMI Res. 8(1):80
Türeci Ö, Löwer M, Schrörs B, Lang M, Tadmor A, Sahin U. (2018)
Challenges towards the realization of individualized cancer vaccines.
Nat Biomed Eng. 19:747
Boegel S, Bukur T, Castle JC, Sahin U. (2018)
In Silico Typing of Classical and Non-classical HLA Alleles from Standard RNA-Seq Reads
Methods Mol Biol. 1802:177-191
Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH. (2018)
Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.
J Immunol Methods. pii: S0022-1759(18)30025-5
Schumacher J, Bacic T, Staritzbichler R, Daneschdar M, Klamp T, Arnold P, Jägle S, Türeci Ö, Markl J, Sahin U. (2018)
Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.
J Nanobiotechnology. 16(1):39
Boegel S, Löwer M, Bukur T, Sorn P, Castle J, Sahin U. (2018)
HLA and proteasome expression body map.
BMC Medical Genomics. 11:36
Sahin U, Türeci Ö. (2018)
Personalized vaccines for cancer immunotherapy.
Science. 359(6382):1355-1360.
Shen L, Tenzer S, Storck W, Hobernik D, Raker VK, Fischer K, Decker S, Dzionek A, Krauthäuser S, Diken M, Nikolaev A, Maxeiner J, Schuster P, Kappel C, Verschoor A, Schild H, Grabbe S, Bros M. (2018)
Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.
J Allergy Clin Immunol. Jan 31. pii: S0091-6749(18)30121-0
Diken M, Chu KK, Brodsky AN. (2018)
Translating Science into Survival: Report on the Third International Cancer Immunotherapy Conference.
Cancer Immunol Res. 6(1):10-13. doi: 10.1158/2326-6066.CIR-17-0656.
Canli Ö, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, Neumann T, Horst D, Löwer M, Sahin U, Greten FR. (2017)
Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis.
Cancer Cell. 2017. 32(6):869-883.
Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD. (2017)
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
Sci. Rep. 2017. 7(1):16892.
Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, Diken M, Kreiter S, Türeci Ö, Sahin U. (2017)
Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins.
Hum. Gene Ther. 2017/09/06 online.
Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H, Reece ST, Sahin U, Tregoning JS. (2017)
Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.
Mol Ther. 2017 Dec 5. pii: S1525-0016(17)30594-4.
Sahu SK, Tiwari N, Pataskar A, Zhuang Y, Borisova M, Diken M, Strand S, Beli P, Tiwari VK. (2017)
FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development.
Nat Commun. 2017 Nov 15;8(1):1523.
Schulz H, Ruppert AK, Herms S, Wolf C, Mirza-Schreiber N, Stegle O, Czamara D, Forstner AJ, Sivalingam S, Schoch S, Moebus S, Pütz B, Hillmer A, Fricker N, Vatter H, Müller-Myhsok B, Nöthen MM, Becker AJ, Hoffmann P, Sander T, Cichon S. (2017)
Genome-wide mapping of genetic determinants influencing DNA methylation and gene expression in human hippocampus.
Nat Commun. 2017 Nov 15;8(1):1511.
Stadler CR, Bahr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Kariko K, Tureci O, Sahin U. (2017)
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
Nat Med. 2017.(7):815-817.
Kong SL, Liu X, Suhaimi NM, Koh KJH, Hu M, Lee DYS, Cima I, Phyo WM, Lee EXW, Tai JA, Foong YM, Vo JH, Koh PK, Zhang T, Ying JY, Lim B, Tan MH, Hillmer AM. (2017)
Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care.
Oncotarget. 2017; 8:68026-68037.
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Kemmer-Brück A, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature. 2017. 547(7662):222-226.
Heilmann-Heimbach S, Herold C, Hochfeld LM, Hillmer AM, Nyholt DR, Hecker J, Javed A, Chew EG, Pechlivanis S, Drichel D, Heng XT, Del Rosario RC, Fier HL, Paus R, Rueedi R, Galesloot TE, Moebus S, Anhalt T, Prabhakar S, Li R, Kanoni S, Papanikolaou G, Kutalik Z, Deloukas P, Philpott MP, Waeber G, Spector TD, Vollenweider P, Kiemeney LA, Dedoussis G, Richards JB, Nothnagel M, Martin NG, Becker T, Hinds DA, Nöthen MM. (2017)
Meta-analysis identifies novel risk loci and yielads systemtic insights into the biology of male-pattern baldness.
Nat Commun. 2017 Mar 8;8:14694.
Diken M, Kranz LM, Kreiter S, Sahin U. (2017)
mRNA: A Versatile Molecule for Cancer Vaccines.
Curr Issues Mol Biol. 2017;22:113-128.
Diken M, Vormehr M, Grunwitz C, Kreiter S, Türeci Ö, Sahin U. (2017)
Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.
Methods Mol Biol.2017;1499:223-236.
Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U. (2017)
The European Regulatory Environment of RNA-Based Vaccines.
Methods Mol Biol. 2017;1499:203-222.
Strenkowska M, Grzela R, Majewski M, Wnek K, Kowalska J, Lukaszewicz M, Zuberek J, Darzynkiewicz E, Kuhn AN, Sahin U, Jemielity J. (2016)
Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.
Nucleic Acids Res. 2016 Nov 16; 44(20):9578-9590 Epub 2016 Oct 7.
Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. (2016)
Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Nanomedicine (Lond) 2016 Oct 11.
Waisman A, Hövelmeyer N, Diefenbach A, Schuppan D, Reddehase MJ, Kleinert H, Kaina B, Grabbe S, Galle PR, Theobald M, Zipp F, Sahin U, Türeci Ö, Kreiter S, Langguth P, Decker H, van Zandbergen G, Schild H. (2016)
Past, present and future of immunology in Mainz.
Cell Immunol 2016.
Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R. (2016)
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.
Oncoimmunology 5(12):e1240859 2016 Oct 7
McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough SM, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O’Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH. (2016)
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes
Clinical Cancer Research 2016
Liu Y, Loewer M, Aluru S, Schmidt B. (2016)
SNVSniffer: an integrated caller for germline and somatic single-nucleotide and indel mutations.
BMC Syst Biol. 2016 Aug 1;10 Suppl 2:47.
Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, Diken M, Kreiter S. (2016)
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice.
Cancer Immunol Immunother 2016 Jul 15.
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature 2016-06-01; advance online publication
Kreiter S, Diken M, Selmi A, Petschenka J, Türeci Ö, Sahin U. (2016)
FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.
Methods Mol Biol. 2016;1428:163-75
Alrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E. (2016)
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.
Nat Commun. 2016 May 25;7:11724.
Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H. (2016)
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Breast Cancer Res Treat. 2016 May 24
Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. (2016)
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Clinical Cancer Research 2016; 22(8):1885-96
Knies D, Klobuch S, Xue SA, Birtel M, Echchannaoui H, Yildiz O, Omokoko T, Guillaume P, Romero P, Stauss H, Sahin U, Herr W, Theobald M, Thomas S, Voss RH. (2016)
An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
Oncotarget 2016.
Kreiter S, Diken M, Pascolo S, Nair SK, Thielemans KM, Geall A. (2016)
The RNA Vaccination Therapy: Advances in an Emerging Field.
Journal of Immunology Research 2016.
Wagner M, Jung J, Koslowski M, Türeci Ö, Tiwari VK, Sahin U. (2016)
Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors.
Methods in molecular biology (Clifton, N.J.) 2016, 1366:53-65.
Kloke BP, Kreiter S, Vormehr M, Diken M, Kuhn AN, Sahin U. (2016)
Actively personalized cancer vaccines–the step into clinical application.
Pharmazie 2016, 1:43-7.
Omokoko TA, Luxemburger U, Bardissi S, Simon P, Utsch M, Breitkreuz A, Türeci Ö, Sahin U. (2016)
Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.
J Immunol Res 2016, 2016:9540975.
Vormehr M, Schrörs B, Boegel S, Löwer M, Türeci Ö, Sahin U. (2015)
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
Journal of Immunology Research 2015, 2015:1-6.
Vormehr M, Diken M, Boegel S, Kreiter S, Türeci Ö, Sahin U. (2015)
Mutanome directed cancer immunotherapy.
Current opinion in immunology 2015, 39:14-22.
Stadler CR, Bähr-Mahmud H, Plum LM, Schmoldt K, Kölsch AC, Türeci Ö, Sahin U. (2015)
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.
OncoImmunology 2015, 5:e1091555.
Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann K, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD. (2015)
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
Journal of virology 2015, 89:11654-11667.
Diken M, Kreiter S, Kloke B, Sahin U. (2015)
Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format.
Progress in tumor research 2015, 42:44-54.
Poleganov MA, Eminli S, Beissert T, Herz S, Moon J, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D, Türeci Ö, Yi K, Hamilton B, Sahin U. (2015)
Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.
Human Gene Therapy 2015, 26:751-766.
Paret C, Simon P, Vormbrock K, Bender C, Kölsch A, Breitkreuz A, Yildiz Ö, Omokoko T, Hubich-Rau S, Hartmann C, Häcker S, Wagner M, Roldan DB, Selmi A, Türeci Ö, Sahin U. (2015)
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Oncotarget 2015, 6:25356-25367.
Kuemmel A, Simon P, Breitkreuz A, Röhlig J, Luxemburger U, Elsäßer A, Schmidt LH, Sebastian M, Sahin U, Türeci Ö, Buhl R. (2015)
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).
Lung Cancer. 2015 Nov;90(2):334-41.
Jiménez Calvente C, Sehgal A, Popov Y, Kim YO, Zevallos V, Sahin U, Diken M, Schuppan D. (2015)
Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis.
Hepatology (Baltimore, Md.) 2015, 62:1285-1297.
Kranz LM, Birtel M, Krienke C, Grunwitz C, Petschenka J, Reuter KC, van de Roemer N, Vascotto F, Vormehr M, Kreiter S, Diken M. (2016)
CIMT 2015: The right patient for the right therapy – Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Human vaccines & immunotherapeutics 2016, 12:213-221. DE
Bidmon N, Attig S, Rae R, Schröder H, Omokoko TA, Simon P, Kuhn AN, Kreiter S, Sahin U, Gouttefangeas C, van der Burg, Sjoerd H, Britten CM. (2015)
Generation of TCR-engineered T cells and their use to control the performance of T cell assays.
Journal of immunology (Baltimore, Md.: 1950) 2015, 194:6177-6189.
White S, Laske K, Welters MJ, Bidmon N, van der Burg, Sjoerd H, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan C. (2014)
Managing Multi-center Flow Cytometry Data for Immune Monitoring.
Cancer informatics 2014, 13:111-122.
Vallazza B, Petri S, Poleganov MA, Eberle F, Kuhn AN, Sahin U. (2015)
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond.
Wiley interdisciplinary reviews. RNA 2015, 6:471-499.
Maaß F, Wüstehube-Lausch J, Dickgießer S, Valldorf B, Reinwarth M, Schmoldt H, Daneschdar M, Avrutina O, Sahin U, Kolmar H. (2015)
Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Journal of peptide science: an official publication of the European Peptide Society 2015, 21:651-660.
Kreiter S, Vormehr M, van de Roemer, Niels, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U. (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature 2015, 520:692-696.
Foerster F, Strobl S, Kaps L, Weng S, Kim YO, Bros M, Diken M, Boegel S, Castle J, Bockamp E, Schuppan D. (2015)
P0311. Balb/c and C57/Bl6 mice exhibit differences in their susceptibility and anti-tumor response to B16F10 melanoma liver metastasis.
Journal of Hepatology 2015, 62:S425.
Kang B, Okwieka P, Schöttler S, Seifert O, Kontermann RE, Pfizenmaier K, Musyanovych A, Meyer R, Diken M, Sahin U, Mailänder V, Wurm FR, Landfester K. (2015)
Tailoring the stealth properties of biocompatible polysaccharide nanocontainers.
Biomaterials 2015, 49:125-134.
Omokoko T, Simon P, Türeci Ö, Sahin U. (2015)
Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.
Oncoimmunology 2015, 4:e1005523.
Boegel S, Scholtalbers J, Löwer M, Sahin U, Castle JC. (2015)
In Silico HLA Typing Using Standard RNA-Seq Sequence Reads.
Methods in molecular biology (Clifton, N.J.) 2015, 1310:247-258.
Scholtalbers J, Boegel S, Bukur T, Byl M, Goerges S, Sorn P, Loewer M, Sahin U, Castle JC. (2015)
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome medicine 2015, 7:118.
Kloke B, Mahr A, Jabulowsky RA, Kutscher S, Rae R, Britten CM. (2014)
Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
Cancer immunology, immunotherapy: CII 2015, 64:923-930.
Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Tureci Ö, Sahin U. (2014)
Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
Cancer Immunology Research 2 (12) (2014) 1230–1244.
Diken M, Boegel S, Grunwitz C, Kranz LM, Reuter K, van de Roemer, Niels, Vascotto F, Vormehr M, Kreiter S. (2014)
CIMT 2014: Next waves in cancer immunotherapy–report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Human vaccines & immunotherapeutics 2014, 10:3090-3100.
Boegel S, Löwer M, Bukur T, Sahin U, Castle JC. (2014)
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Oncoimmunology 2014, 3:e954893.
Boisguérin V, Castle JC, Loewer M, Diekmann J, Mueller F, Britten CM, Kreiter S, Türeci Ö, Sahin U. (2014)
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.
Br J Cancer 2014, 111:1469-1475.
Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg, Sjoerd H, Walter S, Gouttefangeas C. (2014)
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.
Cytometry. Part A: the journal of the International Society for Analytical Cytology 2015, 87:37-48.
Sahin U, Kariko K, Tureci O. (2014)
mRNA-based therapeutics–developing a new class of drugs.
Nature Reviews Drug Discovery 13 (10) (2014) 759–780.
Muhammad K, Alrefai H, Marienfeld R, Pham, Duong Anh Thuy, Murti K, Patra AK, Avots A, Bukur V, Sahin U, Kondo E, Klein-Hessling S, Serfling E. (2014)
NF-κB factors control the induction of NFATc1 in B lymphocytes.
European journal of immunology 2014, 44:3392-3402.
Kuehnle M, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, Wichert G von, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O. (2014)
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.
Cancer immunology, immunotherapy: CII 2014, 63:1273-1284.
Kreiter S, Castle JC, Türeci O, Sahin U. (2012)
Targeting the tumor mutanome for personalized vaccination therapy.
Oncoimmunology 2012, 1:768-769.
Kowalska J, Wypijewska del Nogal, Anna, Darzynkiewicz ZM, Buck J, Nicola C, Kuhn AN, Lukaszewicz M, Zuberek J, Strenkowska M, Ziemniak M, Maciejczyk M, Bojarska E, Rhoads RE, Darzynkiewicz E, Sahin U, Jemielity J. (2014)
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.
Nucleic acids research 2014, 42:10245-10264.
Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg, Sjoerd H, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch, Linda F M, Walter S, Welters, Marij J P, Ottensmeier CH. (2014)
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.
Cancer immunology, immunotherapy: CII 2014, 63:1199-1211.
Reuter S, Martin H, Beckert H, Bros M, Montermann E, Belz C, Heinz A, Ohngemach S, Sahin U, Stassen M, Buhl R, Eshkind L, Taube C. (2014)
The Wnt/β-catenin pathway attenuates experimental allergic airway disease.
Journal of immunology (Baltimore, Md.: 1950) 2014, 193:485-495.
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, Deimling A von, Wick W, Platten M. (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity.
Nature 2014, 512:324-327.
Janetzki S, Britten CM. (2014)
The role of the reporting framework MIATA within current efforts to advance immune monitoring.
Journal of immunological methods 2014, 409:6-8.
Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, Graaf J de, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U. (2014)
Mutated tumor alleles are expressed according to their DNA frequency.
Scientific reports 2014, 4:4743.
Koste L, Beissert T, Hoff H, Pretsch L, Türeci Ö, Sahin U. (2014)
T-cell receptor transfer into human T cells with ecotropic retroviral vectors.
Gene Therapy 21 (5) (2014) 533-538.
Micke P, Mattsson, Johanna Sofia Margareta, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O. (2014)
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
International journal of cancer. Journal international du cancer 2014, 135:2206-2214.
Castle JC, Loewer M, Boegel S, Graaf J de, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U. (2014)
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.
BMC genomics 2014, 15:190.
Schnatbaum K, Schmoldt H, Daneschdar M, Plum LM, Jansong J, Zerweck J, Kühne Y, Masch A, Wenschuh H, Fiedler M, Türeci Ö, Sahin U, Reimer U. (2014)
Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362.
Biotechnology journal 2014, 9:545-554.
Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U. (2013)
mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.
Cancer immunology research 2013, 1:386-392.
Wagner M, Koslowski M, Paret C, Schmidt M, Türeci O, Sahin U. (2013)
NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells.
BMC cancer 2013, 13:570.
Wöll, S., Schlitter, A.M., Dhaene, K., Roller, M., Esposito, I., Sahin, U., Türeci, Ö. (2013)
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Int J Cancer. 2013 Jul 30.
Kloke B, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM. (2013)
Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.
Cancer immunology, immunotherapy: CII 2014, 63:749-755.
Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen K, Khleif SN, Kreiter S, Nielsen M, Rammensee H, Sahin U, Hinz T, Kalinke U. (2013)
The regulatory landscape for actively personalized cancer immunotherapies.
Nature biotechnology 2013, 31:880-882.
Cabezas-Wallscheid N, Eichwald V, Graaf J de, Löwer M, Lehr H, Kreft A, Eshkind L, Hildebrandt A, Abassi Y, Heck R, Dehof AK, Ohngemach S, Sprengel R, Wörtge S, Schmitt S, Lotz J, Meyer C, Kindler T, Zhang D, Kaina B, Castle JC, Trumpp A, Sahin U, Bockamp E. (2013)
Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model.
EMBO Mol Med 2013, 5:1804-1820.
Britten CM, Walter S, Janetzki S. (2013)
Immunological Monitoring to Rationally Guide AAV Gene Therapy.
Frontiers in immunology 2013, 4:273.
McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. (2013)
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).
Cytometry 2013, 83A:728-738.
Diken M, Attig S, Grunwitz C, Kranz L, Simon P, van de Roemer, Niels, Vascotto F, Kreiter S. (2013)
CIMT 2013: advancing targeted therapies–report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.
Human vaccines & immunotherapeutics 2013, 9:2025-2032.
Sahin U, Türeci O. (2013)
Antigen identification using SEREX.
Methods in molecular biology (Clifton, N.J.) 2013, 1061:59-77.
Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJP, van der Burg, Sjoerd H., West M, Chan C, Altan-Bonnet G. (2013)
Hierarchical Modeling for Rare Event Detection and Cell Subset Alignment across Flow Cytometry Samples.
PLoS Comput Biol 2013, 9:e1003130.
.Warminski M, Kowalska J, Buck J, Zuberek J, Lukaszewicz M, Nicola C, Kuhn AN, Sahin U, Darzynkiewicz E, Jemielity J (2013)
The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation.
Bioorganic & medicinal chemistry letters 2013, 23:3753-3758.
Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, Schneider-Stock R, Klinger P, Greten FR, Threadgill DW, Sahin U, Neurath MF. (2013)
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK.
The Journal of clinical investigation 2013, 123:1428-1443.
Scholtalbers J, Rößler J, Sorn P, Graaf J de, Boisguérin V, Castle J, Sahin U. (2013)
Galaxy LIMS for next-generation sequencing.
Bioinformatics (Oxford, England) 2013, 29:1233-1234.
Schröder JC, Läßig AK, Galetzka D, Peters A, Castle JC, Diederich S, Zechner U, Müller-Forell W, Keilmann A, Bartsch O. (2013)
A boy with homozygous microdeletion of NEUROG1 presents with a congenital cranial dysinnervation disorder [Moebius syndrome variant].
Behavioral and brain functions: BBF 2013, 9:7.
Kloke B, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR. (2013)
oward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.
Cancer immunology, immunotherapy: CII 2013, 62:975-981.
Janetzki S, Hoos A, Melief, Cornelis J M, Odunsi K, Romero P, Britten CM. (2013)
Structured reporting of T cell assay results.
Cancer immunity 2013, 13:13.
Boegel S, Löwer M, Schäfer M, Bukur T, Graaf J de, Boisguérin V, Türeci O, Diken M, Castle JC, Sahin U. (2012)
HLA typing from RNA-Seq sequence reads.
Genome medicine 2012, 4:102.
Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters, Marij J P, Ottensmeier C, van der Burg, Sjoerd H, Gouttefangeas C, Britten CM. (2012)
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.
Cancer immunology, immunotherapy: CII 2013, 62:615-627.
Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. (2012)
Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.
Methods in molecular biology (Clifton, N.J.) 2013, 969:235-246.
Grudzien-Nogalska E, Kowalska J, Su W, Kuhn AN, Slepenkov SV, Darzynkiewicz E, Sahin U, Jemielity J, Rhoads RE. (2012)
Synthetic mRNAs with superior translation and stability properties.
Methods in molecular biology (Clifton, N.J.) 2013, 969:55-72.
Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F et al. (2012)
Cancer classification using the Immunoscore: a worldwide task force.
J Transl Med 2012, 10:205.
Löwer M, Renard BY, Graaf J de, Wagner M, Paret C, Kneip C, Türeci O, Diken M, Britten C, Kreiter S, Koslowski M, Castle JC, Sahin U. (2012)
Confidence-based somatic mutation evaluation and prioritization.
PLoS computational biology 2012, 8:e1002714.
Diekmann, J., Löwer, M., Castle, J.C., Kreiter, S., Türeci, Ö., Sahin, U. (2012)
The T Cell Druggable Genome.
European Pharmaceutical Review. Vol. 17. Issue 4. 2012.
Hoetker, M.S., Kiesslich, R., Diken, M., Moehler,M., Galle, P.R., Li, Y., Goetz, M. (2012)
Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor.
Gastrointestinal Endoscopy. July 7, 2012.
Britten, C.M., Janetzki, S., Butterfield, L.H., Ferrari, G., Gouttefangeas, C., Huber, C., Kalos, M., Levitsky, H.I., Maecker, H.T., Melief, C.J., O’Donnell-Tormey, J., Odunsi, K., Old, L.J., Ottenhoff, T.H., Ottensmeier, C., Pawelec, G., Roederer, M., Roep, B.O., Romero, P., van der Burg, S.H., Walter, S., Hoos, A., Davis, M.M. (2012)
T Cell Assays and MIATA: The Essential Minimum for Maximum Impact.
Immunity. 2012 Jul 27;37(1):1-2.
Welters, M.J., Gouttefangeas, C., Ramwadhdoebe, T.H., Letsch, A., Ottensmeier, C.H., Britten, C.M., van der Burg, S.H. (2012)
Harmonization of the intracellular cytokine staining assay.
Cancer Immunol Immunother. 2012 Jul;61(7):967-78.
Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr H et al. (2012)
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18:2695-2703.
Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer, Niels, Graaf J de, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U. (2012)
Exploiting the mutanome for tumor vaccination.
Cancer research 2012, 72:1081-1091.
Krupp M, Marquardt JU, Sahin U, Galle PR, Castle J, Teufel A. (2012)
RNA-Seq Atlas–a reference database for gene expression profiling in normal tissue by next-generation sequencing.
Bioinformatics (Oxford, England) 2012, 28:1184-1185.
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto P, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, Gruijl T de, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F et al. (2011)
Defining the critical hurdles in cancer immunotherapy.
J Transl Med 2011, 9:214.
van der Burg, S. H., Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters, M. J. P., Romero P, Britten CM, Hoos A. (2011)
Harmonization of Immune Biomarker Assays for Clinical Studies.
Science Translational Medicine 2011, 3:108ps44.
Hobohm K, Seppmann T, Britten CM, Hoff H. (2011)
Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany.
Cancer immunology, immunotherapy: CII 2012, 61:137-143.
Hoos A, Britten CM, Huber C, O’Donnell-Tormey J. (2011)
A methodological framework to enhance the clinical success of cancer immunotherapy.
Nat Biotechnol 2011, 29:867-870.
Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U. (2011)
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer research 2011, 71.
Cancer research 2011, 71:6132-6142.
Cancer Res. 2011 Oct 1;71(19):6132-42.
FLT3 ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines.
Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Husemann, Y., Koslowski, M., Huber, C., Türeci, Ö., and Sahin, U. (2011)
Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH. (2011)
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery.
J Transl Med 2011, 9:155.
Moodie Z, Price L, Janetzki S, Britten CM. (2011)
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.
Methods in molecular biology (Clifton, N.J.) 2012, 792:185-196.
Renard BY, Löwer M, Kühne Y, Reimer U, Rothermel A, Türeci O, Castle JC, Sahin U. (2011)
rapmad: Robust analysis of peptide microarray data.
BMC bioinformatics 2011, 12:324.
Türeci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U. (2011)
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals.
Gene 2011, 481:83-92.
Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM. (2011)
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
Journal of translational medicine 2011, 9:108.
Castle JC. (2011)
SNPs occur in regions with less genomic sequence conservation.
PloS one 2011, 6:e20660.
Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. (2011)
Tumor vaccination using messenger RNA: prospects of a future therapy.
Current opinion in immunology 2011, 23:399-406.
Schneider S, Carra G, Sahin U, Hoy B, Rieder G, Wessler S. (2011)
Complex cellular responses of Helicobacter pylori-colonized gastric adenocarcinoma cells.
Infection and immunity 2011, 79:2362-2371.
Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen T, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van der Burg, S. H., Whiteside TL, Wigginton JM, Marincola F et al. (2011)
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
Clinical Cancer Research 2011, 17:3064-3076.
Diken, M., Kreiter, S., Selmi, A., Britten, C.M., Huber, C., Türeci, Ö., and Sahin, U. (2011)
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.
Gene Ther. 2011 Jul;18(7):702-8.
Klamp T, Schumacher J, Huber G, Kühne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Türeci Ö, Sahin U. (2011)
Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases.
Cancer research 2011, 71:516-527.
Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. (2011)
Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.
RNA biology 2011, 8:35-43.
Kettner C, Field D, Sansone S, Taylor C, Aerts J, Binns N, Blake A, Britten CM, Marco A de, Fostel J, Gaudet P, González-Beltrán A, Hardy N, Hellemans J, Hermjakob H, Juty N, Leebens-Mack J, Maguire E, Neumann S, Orchard S, Parkinson H, Piel W, Ranganathan S, Rocca-Serra P, Santarsiero A, Shotton D, Sterk P, Untergasser A, Whetzel PL. (2010)
Meeting Report from the Second “Minimum Information for Biological and Biomedical Investigations” (MIBBI) workshop.
Stand. Genomic Sci. 2010, 3:259-266.
Singh SK, Laske K, Gouttefangeas C, Britten CM, Welters, Marij J P. (2010)
CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.
Cancer immunology, immunotherapy: CII 2011, 60:443-450.
Britten CM, Janetzki S, van der Burg, S H, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief, C J M, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. (2010)
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
Cancer immunology, immunotherapy: CII 2011, 60:15-22.
Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U:. (2010)
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
Cancer research 2010, 70:9031-9040.
Janetzki S, Price L, Britten CM, van der Burg, S. H., Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. (2010)
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells.
Cancer Immunol Immunother 2010, 59:609-618.
Koslowski, M., Luxemburger, U., Türeci, Ö., and Sahin, U. (2010)
Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1alpha.
Oncogene. 2011 Feb 17;30(7):876-82.
Gorr, T.A., Wichmann, D., Pilarsky, C., Theurillat, J.P., Fabrizius, A., Laufs, T., Bauer, T., Koslowski, M., Horn, S., and Burmester, T., et al. (2010)
Old proteins – new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells.
Acta Physiol (Oxf). 2011 Jul;202(3):563-81
Castle JC, Armour CD, Löwer M, Haynor D, Biery M, Bouzek H, Chen R, Jackson S, Johnson JM, Rohl CA, Raymond CK. (2010)
Digital genome-wide ncRNA expression, including SnoRNAs, across 11 human tissues using polyA-neutral amplification.
PloS one 2010, 5:e11779.
Bland, C.S., Wang, E.T., Vu, A., David, M.P., Castle, J.C., Johnson, J.M., Burge, C.B., and Cooper, T.A. (2010)
Global regulation of alternative splicing during myogenic differentiation.
Nucleic Acids Res. 2010 Nov;38(21):7651-64.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters, M J P, Ottensmeier C, van der Burg, S H, Britten CM. (2010)
Response definition criteria for ELISPOT assays revisited.
Cancer immunology, immunotherapy: CII 2010, 59:1489-1501.
Castle JC, Biery M, Bouzek H, Xie T, Chen R, Misura K, Jackson S, Armour CD, Johnson JM, Rohl CA, Raymond CK. (2010)
DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing.
BMC genomics 2010, 11:244.
Tang ST, van Meijgaarden, Krista E, Caccamo N, Guggino G, Klein MR, van Weeren P, Kazi F, Stryhn A, Zaigler A, Sahin U, Buus S, Dieli F, Lund O, Ottenhoff, Tom H M. (2010)
Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis.
Journal of immunology (Baltimore, Md.: 1950) 2011, 186:1068-1080.
Mander A, Gouttefangeas C, Ottensmeier C, Welters, M J P, Low L, van der Burg, S H, Britten CM. (2010)
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
Cancer immunology, immunotherapy: CII 2010, 59:619-627.